Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia
The Medical Letter on Drugs and Therapeutics · 06.01.2025 · 67 (1719) · 5-6
DOI: 10.58347/tml.2025.1719b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.01.2025. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved pilocarpine 0.4% preservative-free ophthalmic solution (Qlosi – Orasis) for treatment of presbyopia in adults. Pilocarpine 1.25% ophthalmic solution (Vuity) was approved in 2021 for the same indication.1 Pilocarpine 1%, 2%, and 4% ophthalmic solutions (Isopto Carpine, and others) have been available for years for treatment of glaucoma, but local (e.g., blurry vision and instillation-site pain) and systemic (e.g., sweating and GI disturbances) adverse effects have limited their use.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2025). Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia. The Medical Letter on Drugs and Therapeutics, 67(1719), 5-6. https://doi.org/10.58347/tml.2025.1719b
Vancouver
Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia. The Medical Letter on Drugs and Therapeutics. 2025;67(1719):5-6. doi:10.58347/tml.2025.1719b
BibTeX
@article{euvimed2025,
title = {Qlosi — Pilocarpine 0.4% Ophthalmic Solution for Presbyopia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2025},
volume = {67},
number = {1719},
pages = {5--6},
doi = {10.58347/tml.2025.1719b}
}
EUVIMED